TrialGynecologic oncology2014

A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.

Richard T Penson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.